

Table 2.9. Cohort studies of combined estrogen–progestogen menopausal therapy and ovarian cancer

Reference, location study period	Age at recruitment (yrs)	Size of cohort	Average of follow-up (yrs)	Total no. of cases	Histo-logical diagnosis	Subsites	Hormone therapy (type/regimen)	No. of cases	Relative risk (95% CI)	Comments
Danforth <i>et al.</i> (2007), USA, 1976–2002	30–55	82 905		389–	primary epithelial ovarian cancer	All epithelial ovarian tumours	E+P	82	1.04 (0.82–1.32)	Adjusted for age, parity, duration of oral contraceptive use, tubal ligation, age at natural menopause, age at menarche.
							Serous Endometrioid	49	1.12 (0.84–1.51)	
								15	1.04 (0.53–2.03)	
						All epithelial ovarian tumours	Never	167		
							Past	88	1.00 (0.77–1.31)	
							<5 y	57	0.88 (0.64–1.19)	
							≥5 y	31	1.52 (1.01–2.27)	
							Current	134	1.23 (0.97–1.57)	
							<5 y	40	1.01 (0.70–1.43)	
						Serous	≥5 y	94	1.41 (1.07–1.86)	
							Never	96		
							Past	51	0.98 (0.69–1.40)	
							<5 y	32	0.83 (0.55–1.25)	
							≥5 y	19	1.60 (0.95–2.68)	
							Current	86	1.43 (1.04–1.96)	
						Endometrioid	<5 y	23	1.09 (0.68–1.75)	
≥5 y	63	1.66 (1.17–2.36)								
Never	21									
Past	16	1.68 (0.85–3.33)								
<5 y	9	1.25 (0.56–2.80)								
≥5 y	7	3.59 (1.41–9.14)								
Current	23	1.61 (0.85–3.05)								
	<5 y	8	1.38 (0.59–3.25)							
	≥5 y	15	1.86 (0.89–3.91)							

Table 2.9. Cohort studies of combined estrogen–progestogen menopausal therapy and ovarian cancer

Reference, location study period	Age at recruitment (yrs)	Size of cohort	Average of follow-up (yrs)	Total no. of cases	Histo-logical diagnosis	Subsites	Hormone therapy (type/regimen)	No. of cases	Relative risk (95% CI)	Comments	
Lacey <i>et al.</i> (2006), USA, 1995–2000	50–71	97 638	2.0 w/ ovarian cancer 4.0 w/o ovarian cancer	214			Never	73	1.50 (1.03–2.19)	Adjusted for continuous age (years), race (white, other/unknown), menopausal status (premenopausal, postmenopausal, or unknown), duration of oral contraceptive use (none, <10 years)	
							E+P only	50			
							Duration of E+P-only use, y				
							≤1	7			1.20 (0.55–2.62)
							2–4	11			1.24 (0.65–2.39)
							5–9	13			1.30 (0.71–2.39)
							≥10	19			2.15 (1.28–3.62)
							Recency of E+P-only use				
							Former	8			1.29 (0.62–2.68)
							<10	25			1.33 (0.82–2.14)
							≥10	17			2.08 (1.21–3.57)
							Regimen and duration				
							Sequential, y				
							≤1	1			2.53 (0.35–18.5)
2–4	3	2.35 (0.72–7.69)									
≥5	13	3.09 (1.68–5.68)									
Continuous, y											
≤1	5	2.06 (0.82–5.13)									
2–4	5	1.12 (0.45–2.82)									
≥5	15	1.82 (1.03–3.23)									

Table 2.9. Cohort studies of combined estrogen–progestogen menopausal therapy and ovarian cancer

Reference, location study period	Age at recruitment (yrs)	Size of cohort	Average of follow-up (yrs)	Total no. of cases	Histo-logical diagnosis	Subsites	Hormone therapy (type/regimen)	No. of cases	Relative risk (95% CI)	Comments
Beral <i>et al.</i> (2007), UK, 1996–2004	57.2	948 567	5.3 for incident ovarian cancer 6.9 for death				Duration of use			Stratified by age and hysterectomy status, and adjusted by area of residence, socioeconomic group, time since menopause, parity, body-mass index, alcohol consumption, and use of oral contraceptives
							<5 years	141	1.09 (0.91–1.30)	
							≥5 years	263	1.17 (1.02–1.34)	
							By constituent			
							(levo) Norgestrel	160	1.13 (0.95–1.33)	
							Norethisterone	172	1.22 (1.04–1.44)	
							Medroxyproges- terone acetate	69	0.99 (0.77–1.26)	
By regimen										
Continuous	162	1.13 (0.95–1.33)								
Sequential	234	1.14 (0.98–1.32)								